Cargando…

A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India

INTRODUCTION: Despite a very large number of patients being covered under antiretroviral therapy (ART), there are limited data in the Indian population regarding second-line ART. Hence, this study was undertaken to evaluate the efficacy of second-line ART. MATERIALS AND METHODS: After consultation w...

Descripción completa

Detalles Bibliográficos
Autores principales: Modi, Jigar P., Kubavat, Amita, Mundhava, Shailesh, Lalwani, Usha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532480/
https://www.ncbi.nlm.nih.gov/pubmed/31143861
http://dx.doi.org/10.4103/ijstd.IJSTD_53_18
_version_ 1783421038139277312
author Modi, Jigar P.
Kubavat, Amita
Mundhava, Shailesh
Lalwani, Usha
author_facet Modi, Jigar P.
Kubavat, Amita
Mundhava, Shailesh
Lalwani, Usha
author_sort Modi, Jigar P.
collection PubMed
description INTRODUCTION: Despite a very large number of patients being covered under antiretroviral therapy (ART), there are limited data in the Indian population regarding second-line ART. Hence, this study was undertaken to evaluate the efficacy of second-line ART. MATERIALS AND METHODS: After consultation with the physician of ART Plus Centre, the patient was interviewed, and details of patients' case record were obtained. In our ART Plus Centre, CD4 count has been done at the start and after 6 months of second-line ART which were recorded as effectiveness indicator of second-line ART. RESULTS: Out of seventy patients, 16 (22.86%) had a history of second-line ART from private ART clinics and 54 (77.14%) patients were transferred from other government ART centers. The most common reason to start second-line ART was immunological failure in 27 patients. The mean increase in CD4 count of 106.09 cells/mm(3) was observed after 6 months of second-line ART in 63 patients. The mean increase in CD4 count (57.16%) after 6 months was statistically significant (P < 0.05) with tenofovir + lamivudine + atazanavir/ritonavir regimen in forty patients. CONCLUSIONS: Irrational practice by private hospitals limits treatment options, with increasing the chances of drug resistance. On the other hand, the National AIDS Control Organization-sponsored second-line ART was found to be effective as 84.12% of patients had improvement in their mean CD4 count.
format Online
Article
Text
id pubmed-6532480
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Medknow Publications & Media Pvt Ltd
record_format MEDLINE/PubMed
spelling pubmed-65324802019-05-29 A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India Modi, Jigar P. Kubavat, Amita Mundhava, Shailesh Lalwani, Usha Indian J Sex Transm Dis AIDS Original Article INTRODUCTION: Despite a very large number of patients being covered under antiretroviral therapy (ART), there are limited data in the Indian population regarding second-line ART. Hence, this study was undertaken to evaluate the efficacy of second-line ART. MATERIALS AND METHODS: After consultation with the physician of ART Plus Centre, the patient was interviewed, and details of patients' case record were obtained. In our ART Plus Centre, CD4 count has been done at the start and after 6 months of second-line ART which were recorded as effectiveness indicator of second-line ART. RESULTS: Out of seventy patients, 16 (22.86%) had a history of second-line ART from private ART clinics and 54 (77.14%) patients were transferred from other government ART centers. The most common reason to start second-line ART was immunological failure in 27 patients. The mean increase in CD4 count of 106.09 cells/mm(3) was observed after 6 months of second-line ART in 63 patients. The mean increase in CD4 count (57.16%) after 6 months was statistically significant (P < 0.05) with tenofovir + lamivudine + atazanavir/ritonavir regimen in forty patients. CONCLUSIONS: Irrational practice by private hospitals limits treatment options, with increasing the chances of drug resistance. On the other hand, the National AIDS Control Organization-sponsored second-line ART was found to be effective as 84.12% of patients had improvement in their mean CD4 count. Medknow Publications & Media Pvt Ltd 2019 /pmc/articles/PMC6532480/ /pubmed/31143861 http://dx.doi.org/10.4103/ijstd.IJSTD_53_18 Text en Copyright: © 2019 Indian Journal of Sexually Transmitted Diseases and AIDS http://creativecommons.org/licenses/by-nc-sa/4.0 This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Original Article
Modi, Jigar P.
Kubavat, Amita
Mundhava, Shailesh
Lalwani, Usha
A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title_full A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title_fullStr A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title_full_unstemmed A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title_short A prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at Antiretroviral Therapy Plus Centre in India
title_sort prospective study to evaluate efficacy of second-line antiretroviral therapy given to human immunodeficiency virus patients at antiretroviral therapy plus centre in india
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6532480/
https://www.ncbi.nlm.nih.gov/pubmed/31143861
http://dx.doi.org/10.4103/ijstd.IJSTD_53_18
work_keys_str_mv AT modijigarp aprospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT kubavatamita aprospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT mundhavashailesh aprospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT lalwaniusha aprospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT modijigarp prospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT kubavatamita prospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT mundhavashailesh prospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia
AT lalwaniusha prospectivestudytoevaluateefficacyofsecondlineantiretroviraltherapygiventohumanimmunodeficiencyviruspatientsatantiretroviraltherapypluscentreinindia